Biography



<< Back

David Gill

Throughout his career, David has served in a number of corporate officer roles and as a director of various publicly-traded life science companies. He served as the president and chief financial officer of EndoChoice, a public medical device company focused on gastrointestinal disease from April 2016, through the sale of the company to Boston Scientific in November 2016, and as chief financial officer from August 2014 to November 2016. Prior to Endochoice, David served as chief financial officer of INC Research Holdings Inc., now known as Syneos, after serving as a board member and audit committee chairman of the company. Earlier in his career he served in senior leadership roles for several medical device companies including TransEnterix, NxStage Medical, CTI Molecular Imaging, Inc., Novoste Corporation and Dornier Medical. David currently serves as chairman of the board of Melinta Therapeutics, and is on the board of directors at Evolus, Y-mAbs Therapeutics and Strata Skin Sciences. He has led initial public offerings for four companies and has raised more than $1.2 billion in equity and debt over his career.

David holds a BS degree, cum laude, in accounting from Wake Forest University and an MBA degree, with honors, from Emory University, and was formerly a certified public accountant.









© 2020 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Dublin Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
MLR-0010 V16 03/2020

  • Ireland Address:
    Suite 206, Fitzwilliam Hall
    Fitzwilliam Place, Dublin 2, D02 T292
    Ireland
  • U.S. Address:
    900 Northbrook Drive, Suite 200
    Trevose, PA 19053
    United States

Phone: +1 610-254-9200
[email protected]

Privacy Statement
Compliance Program